Interferon-γ induces senescence in normal human melanocytes

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Wang, Suiquan ^a   Zhou, Miaoni ^a   Lin, Fuquan ^a   Liu, Dongyin ^a   Hong, Weisong ^a   Lu, Liangjun ^a,b   Zhu, Yiping ^a,b   Xu, Aie ^a  

^a THE THIRD PEOPLE S HOSPITAL OF HANGZHOU   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BETA GALACTOSIDASE; GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE 2; MESSENGER RNA; PIFITHRIN ALPHA; PROTEIN P21; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; STAT1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 2A; IRON BINDING PROTEIN; IRON-BINDING SEMINAL PLASMA ANTIGEN; JAK2 PROTEIN, HUMAN; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; MELANOCYTE; MRNA EXPRESSION ASSAY; PROTEIN EXPRESSION; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; SENESCENCE; SIGNAL TRANSDUCTION; VITILIGO; AGING; CELL AGING; CELL CULTURE; CELL CYCLE; CELL CYCLE CHECKPOINT; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

ACETYLCYSTEINE; AGING; APOPTOSIS; BETA-GALACTOSIDASE; CELL AGING; CELL CYCLE; CELL CYCLE CHECKPOINTS; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-6; IRON-BINDING PROTEINS; JANUS KINASE 1; JANUS KINASE 2; MELANOCYTES; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899833937     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093232     Document Type: Article

References (55)

1. Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, et al. (2012) Vitiligo Global Issue Consensus Conference Panelists. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res 25: E1-13.
2. Taïeb A, Picardo M (2009) Clinical practice. Vitiligo. N Engl J Med 360: 160-169.
3. van den Boorn JG, Konijnenberg D, Dellemijn TA, van der Veen JP, Bos JD, et al. (2009) Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 129: 2220-2232.
4. Steitz J, Wenzel J, Gaffal E, Tüting T (2004) Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo. Eur J Cell Biol 83: 797-803.
5. Lili Y, Yi W, Ji Y, Yue S, Weimin S, et al. (2012) Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PLoS One 7: e37513.
6. McCully ML, Ladell K, Hakobyan S, Mansel RE, Price DA, et al. (2012) Epidermis instructs skin homing receptor expression in human T cells. Blood 120: 4591-4598.
7. Biedermann T, Lametschwandtner G, Tangemann K, Kund J, Hinteregger S, et al. (2006) IL-12 instructs skin homing of human Th2 cells. J Immunol 177: 3763-3770.
8. Dell'anna ML, Cario-André M, Bellei B, Taieb A, Picardo M (2012) In vitro research on vitiligo: strategies, principles, methodological options and common pitfalls. Exp Dermatol 21: 490-496.
9. 2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Investig Dermatol Symp Proc 4: 91-96.
10. Bellei B, Pitisci A, Ottaviani M, Ludovici M, Cota C, et al. (2013) Vitiligo: A Possible Model of Degenerative Diseases. PLoS One 8: e59782.
11. Hirobe T (2005) Role of keratinocyte-derived factors involved in regulating the proliferation and differentiation of mammalian epidermal melanocytes. Pigment Cell Melanoma Res 18: 2-12.
12. Basak PY, Adiloglu AK, Ceyhan AM, Tas T, Akkaya VB (2009) The role of helper and regulatory T cells in the pathogenesis of vitiligo. J Am Acad Dermatol 60: 256-260.
13. Attwa E, Gamil H, Assaf M, Ghonemy S (2012) Over-expression of tumor necrosis factor-a in vitiligo lesions after narrow-band UVB therapy: an immunohistochemical study. Arch Dermatol Res 304: 823-830.
14. Seif El Nasr H, Shaker O, Fawzi MM, El-Hanafi G (2013) Basic fibroblast growth factor and tumour necrosis factor alpha in vitiligo and other hypopigmented disorders: suggestive possible therapeutic targets. J Eur Acad Dermatol Venereol 27: 103-108.
15. Klarquist J, Denman CJ, Hernandez C, Wainwright DA, Strickland FM, et al. (2010) Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res 23: 276-286.
16. Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, et al. (2012) A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+T cell accumulation in the skin. J Invest Dermatol 132: 1869-1876.
17. Gregg RK, Nichols L, Chen Y, Lu B, Engelhard VH (2010) Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice. J Immunol 184: 1909-1917.
18. Bach EA, Aguet M, Schreiber RD (1997) The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 15: 563-591.
19. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, et al. (1999) Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 163: 4647-4650.
20. Frucht DM, Fukao T, Bogdan C, Schindler H, O'Shea JJ, et al. (2001) IFNgamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol 22: 556-560.
21. Flaishon L, Hershkoviz R, Lantner F, Lider O, Alon R, et al. (2000) Autocrine secretion of interferon gamma negatively regulates homing of immature B cells. J Exp Med 192: 1381-1388.
22. Sen GC (2001) Viruses and interferons. Annu Rev Microbiol 55: 255-281.
23. Schroder K, Hertzog PJ, Ravasi T, Hume DA (2004) Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75: 163-189.
24. Hong WS, Hu DN, Qian GP, McCormick SA, Xu AE (2011) Ratio of size of recipient and donor areas in treatment of vitiligo by autologous cultured melanocyte transplantation. Br J Dermatol 165: 520-525.
25. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS (2010) The essence of senescence. Genes Dev 24: 2463-2479.
26. Beauséjour CM, Krtolica A, Galimi F, Narita M, Lowe SW, et al. (2003) Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 22: 4212-4222.
27. Bansal R, Nikiforov MA (2010) Pathways of oncogene-induced senescence in human melanocytic cells. Cell Cycle 9: 2782-2788.
28. Herbig U, Jobling WA, Chen BP, Chen DJ, Sedivy JM (2004) Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell 14: 501-513.
29. Catalano A, Rodilossi S, Caprari P, Coppola V, Procopio A (2005) 5-Lipoxygenase regulates senescence-like growth arrest by promoting ROS-dependent p53 activation. EMBO J 24: 170-179.
30. Macip S, Igarashi M, Fang L, Chen A, Pan ZQ, et al. (2002) Inhibition of p21-mediated ROS accumulation can rescue p21-induced senescence. EMBO J 21: 2180-2188.
31. Roy N, Stoyanova T, Dominguez-Brauer C, Park HJ, Bagchi S, et al. (2010) DDB2, an essential mediator of premature senescence. Mol Cell Biol 30: 2681-2692.
32. Toosi S, Orlow SJ, Manga P (2012) Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8. J Invest Dermatol 132: 2601-2609.
33. Imokawa G (2004) Autocrine and paracrine regulation of melanocytes in human skin and in pigmentary disorders. Pigment Cell Melanoma Res 17: 96-110.
34. Schallreuter KU, Bahadoran P, Picardo M, Slominski A, Elassiuty YE, et al. (2008) Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else. Exp Dermatol 17: 139-140.
35. Gauthier Y, Cario-Andre M, Lepreux S, Pain C, Taïeb A (2003) Melanocyte detachment after skin friction in non lesional skin of patients with generalized vitiligo. Br J Dermatol 148: 95-101.
36. Zhou Z, Li CY, Li K, Wang T, Zhang B, et al. (2009) Decreased methionine sulphoxide reductase A expression renders melanocytes more sensitive to oxidative stress: a possible cause for melanocyte loss in vitiligo. Br J Dermatol 161: 504-509.
37. Bandyopadhyay D, Timchenko N, Suwa T, Hornsby PJ, Campisi J, et al. (2001) The human melanocyte: a model system to study the complexity of cellular aging and transformation in non-fibroblastic cells. Exp Gerontol 36: 1265-1275.
38. Sviderskaya EV, Hill SP, Evans-Whipp TJ, Chin L, Orlow SJ, et al. (2002) p16(Ink4a) in melanocyte senescence and differentiation. J Natl Cancer Inst 94: 446-454.
39. Costin GE, Valencia JC, Wakamatsu K, Ito S, Solano F, et al. (2005) Mutations in dopachrome tautomerase (Dct) affect eumelanin/pheomelanin synthesis, but do not affect intracellular trafficking of the mutant protein. Biochem J 391: 249-259.
40. Marks MS, Seabra MC (2001) The melanosome: membrane dynamics in black and white. Nat Rev Mol Cell Biol 2: 738-748.
41. Zuo S, Liu C, Wang J, Wang F, Xu W, et al. (2012) IGFBP-rP1 induces p21 expression through a p53-independent pathway, leading to cellular senescence of MCF-7 breast cancer cells. J Cancer Res Clin Oncol 138: 1045-1055.
42. Sayama K, Shirakata Y, Midorikawa K, Hanakawa Y, Hashimoto K (1999) Possible involvement of p21 but not of p16 or p53 in keratinocyte senescence. J Cell Physiol 179: 40-44.
43. Sviderskaya EV, Gray-Schopfer VC, Hill SP, Smit NP, Evans-Whipp TJ, et al. (2003) p16/Cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression. J Natl Cancer Inst 95: 723-732.
44. Ishihara K, Hirano T (2002) IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 13: 357-368.
45. Kishimoto T (2005) Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 23: 1-21.
46. Norose K, Yano A, Wang XC, Tokushima T, Umihira J, et al. (1994) Dominance of activated T cells and interleukin-6 in aqueous humor in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 35: 33-39.
47. Moretti S, Spallanzani A, Amato L, Hautmann G, Gallerani I, et al. (2002) New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Melanoma Res 15: 87-92.
48. Kirnbauer R, Charvat B, Schauer E, Köck A, Urbanski A, et al. (1992) Modulation of intercellular adhesion molecule-1 expression on human melanocytes and melanoma cells: evidence for a regulatory role of IL-6, IL-7, TNF beta, and UVB light. J Invest Dermatol 98: 320-326.
49. Mycko MP, Cwiklinska H, Walczak A, Libert C, Raine CS, et al. (2008) A heat shock protein gene (Hsp70.1) is critically involved in the generation of the immune response to myelin antigen. Eur J Immunol 38: 1999-2013.
50. Mycko MP, Cwiklinska H, Szymanski J, Szymanska B, Kudla G, et al. (2004) Inducible heat shock protein 70 promotes myelin autoantigen presentation by the HLA class II. J Immunol 177: 4168-4177.
51. Mosenson JA, Zloza A, Klarquist J, Barfuss AJ, Guevara-Patino JA, et al. (2012) HSP70i is a critical component of the immune response leading to vitiligo. Pigment Cell Melanoma Res 25: 88-98.
52. Denman CJ, McCracken J, Hariharan V, Klarquist J, Oyarbide-Valencia K, et al. (2008) HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo. J Invest Dermatol 128: 2041-2048.
53. Kroll TM, Bommiasamy H, Boissy RE, Hernandez C, Nickoloff BJ, et al. (2005) 4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J Invest Dermatol 124: 798-806.
54. Mosenson JA, Zloza A, Nieland JD, Garrett-Mayer E, Eby JM, et al. (2013) Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med 5: 174ra28.
55. Laddha NC, Dwivedi M, Mansuri MS, Gani AR, Ansarullah M, et al. (2013) Vitiligo: interplay between oxidative stress and immune system. Exp Dermatol 22: 245-250.